이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중등도에서 중증 플라크 건선을 가진 참가자에서 위약 및 우스 테키 누맙과 비교하여 JNJ-77242113의 효능 및 안전성을 평가하는 연구 (ICONIC-ASCEND)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

3 상 다기관, 무작위, 이중 맹검, 위약 대조 및 Ustekinumab 활성 비교 제어 연구는 중등도 내지 중증 플라크 건선을 갖는 참가자의 치료를위한 JNJ-77242113의 효능 및 안전성을 평가하기위한 Ustekinumab 활성 비교 제어 연구

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

연구 개요

연구 유형

중재적

등록 (실제)

752

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Aalborg, 덴마크, 9100
        • Aalborg Sygehus Syd
      • Aarhus, 덴마크, 8200
        • Aarhus University Hospital
      • Hellerup, 덴마크, 2900
        • Gentofte Hospital
      • København NV, 덴마크, 2400
        • Bispebjerg Hospital
      • Odense, 덴마크, 5000
        • Odense University Hospital
      • Roskilde, 덴마크, 4000
        • Sjællands University hospital
      • Augsburg, 독일, 86179
        • Klinikum Augsburg
      • Bad Bentheim, 독일, 48455
        • Fachklinik Bad Bentheim
      • Berlin, 독일, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Bonn, 독일, 53127
        • Universitatsklinikum Bonn
      • Bramsche, 독일, 49565
        • Studienzentrum an der Hase GbR
      • Darmstadt, 독일, 64283
        • Rosenpark Research GmbH
      • Dresden, 독일, 01307
        • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
      • Friedrichshafen, 독일, 88045
        • Derma-Study-Center Friedrichshafen GmbH
      • Kiel, 독일, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Langenau, 독일, 89129
        • Studienzentrum Dr Schwarz Germany
      • Mahlow, 독일, 15831
        • Dermatologie Mahlow
      • Mainz, 독일, 55128
        • Gemeinschaftspraxis Dres. Quist
      • Münster, 독일, 48149
        • Universitaetsklinikum Muenster
      • Witten, 독일, 58453
        • Hautarztpraxis
    • Alabama
      • Birmingham, Alabama, 미국, 35244
        • Cahaba Research Inc
    • California
      • Encinitas, California, 미국, 92024
        • California Dermatology & Clinical Research Institute
      • Encino, California, 미국, 91436
        • T Joseph Raoof Md Inc
      • Fountain Valley, California, 미국, 92708
        • First OC Dermatology
      • Oceanside, California, 미국, 92056
        • Dermatologist Medical Group of North County, Inc.
      • Rocklin, California, 미국, 95765
        • NorCal Clinical Research
      • Sacramento, California, 미국, 95815
        • Integrative Skin Science and Research
      • San Diego, California, 미국, 92103
        • MedDerm Associates
      • Santa Ana, California, 미국, 92701
        • Southern California Dermatology
      • Sylmar, California, 미국, 91342
        • Olive View-UCLA Education & Research Institute
    • Connecticut
      • Farmington, Connecticut, 미국, 06030
        • University of Conn Health Center
    • Florida
      • Miami, Florida, 미국, 33155
        • Bioclinical Research Alliance Inc.
      • Miami, Florida, 미국, 33126
        • Driven Research LLC
      • Ocala, Florida, 미국, 34470
        • Renstar Medical Research
      • Tampa, Florida, 미국, 33613
        • Forcare Clinical Research Inc
    • Georgia
      • Alpharetta, Georgia, 미국, 30022
        • Hamilton Research LLC
    • Illinois
      • Skokie, Illinois, 미국, 60076
        • Northshore Medical Group
    • Indiana
      • Plainfield, Indiana, 미국, 46168
        • Indiana Clinical Trial Center
    • Iowa
      • Iowa City, Iowa, 미국, 52242
        • University of Iowa
    • Kentucky
      • Bowling Green, Kentucky, 미국, 42104
        • Equity Medical
    • Massachusetts
      • Boston, Massachusetts, 미국, 02111
        • Tufts Medical Center
      • Brighton, Massachusetts, 미국, 02135
        • Metro Boston Clinical Partners
    • Michigan
      • Caledonia, Michigan, 미국, 49316
        • The Derm Institute of West Michigan
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Hospital
      • Fort Gratiot, Michigan, 미국, 48059
        • Hamzavi Dermatology
      • Troy, Michigan, 미국, 48084
        • Somerset Skin Centre
    • Minnesota
      • New Brighton, Minnesota, 미국, 55112
        • Minnesota Clinical Study Center
    • Missouri
      • Kirksville, Missouri, 미국, 63501
        • Cleaver Dermatology
      • Saint Joseph, Missouri, 미국, 64506
        • MediSearch Clinical Trials
    • New York
      • New York, New York, 미국, 10075
        • Sadick Research Group
      • New York, New York, 미국, 10028
        • Mount Sinai Doctors Dermatology
    • North Carolina
      • Wilmington, North Carolina, 미국, 28405
        • Wilmington Dermatology Center
    • Ohio
      • Boardman, Ohio, 미국, 44512
        • Optima Research
      • Mayfield Heights, Ohio, 미국, 44124
        • Apex Dermatology Mayfield Heights
    • Oregon
      • Portland, Oregon, 미국, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, 미국, 97201
        • Oregon Medical Research Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19114
        • Clinical Research Philadelphia
      • Pittsburgh, Pennsylvania, 미국, 15213
        • UPMC Department of Dermatology
    • South Dakota
      • Rapid City, South Dakota, 미국, 57702
        • Health Concepts
    • Tennessee
      • Nashville, Tennessee, 미국, 37211
        • Advanced Research Experts PLLC
    • Texas
      • Arlington, Texas, 미국, 76011
        • Arlington Research Center, Inc.
      • Dallas, Texas, 미국, 75231
        • Modern Research Associates PLLC
      • Houston, Texas, 미국, 77004
        • Center for Clinical Studies 1
      • San Antonio, Texas, 미국, 78218
        • Texas Dermatology and Laser Specialists
      • San Antonio, Texas, 미국, 78213
        • Progressive Clinical Research
      • Webster, Texas, 미국, 77598
        • Center for Clinical Studies
    • Utah
      • West Valley City, Utah, 미국, 84120
        • Kalo Clinical Research
    • Washington
      • Mill Creek, Washington, 미국, 98012
        • Frontier Derm Partners CRO, LLC
      • Brussels, 벨기에, 1090
        • UZ Brussel
      • Ghent, 벨기에, 9000
        • Ghent University Hospital
      • Ghent, 벨기에, 9000
        • AZ St. Lucas
      • Leuven, 벨기에, 3000
        • Universitair Ziekenhuis Leuven
      • Liège, 벨기에, 4000
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Maldegem, 벨기에, 9990
        • Dermatologie Maldegem
      • Alicante, 스페인, 03010
        • Hosp. Gral. Univ. Dr. Balmis
      • Barakaldo, 스페인, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, 스페인, 08036
        • Hosp. Clinic de Barcelona
      • Granada, 스페인, 18016
        • Hosp. Univ. San Cecilio
      • Madrid, 스페인, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, 스페인, 28006
        • Hosp. Univ. de La Princesa
      • Madrid, 스페인, 28002
        • Grupo Dermatologico Y Estetico Pedro Jaen
      • Manises, 스페인, 46940
        • Hosp. de Manises
      • Santiago Compostela, 스페인, 15706
        • Hosp. Clinico Univ. de Santiago
      • Seville, 스페인, 41009
        • Hosp. Virgen Macarena
      • Seville, 스페인, 41014
        • Hosp. Ntra. Sra. de Valme
      • Valencia, 스페인, 46026
        • Hosp. Univ. I Politecni La Fe
      • Villajoyosa, 스페인, 03570
        • Hosp. de La Marina Baixa
      • Zaragoza, 스페인, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Zaragoza, 스페인, 50009
        • Hosp. Univ. Miguel Servet
      • Barrio Gral Paz Cba Capital, 아르헨티나, X5000
        • Consultora Integral de Salud SRL
      • Buenos Aires, 아르헨티나, B1643CRO
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires, 아르헨티나, C1417EYG
        • Mindout Research
      • Buenos Aires, 아르헨티나, C1425
        • Instituto de Neumonologia y Dermatologia
      • CABA, 아르헨티나, C1061AAS
        • CIPREC
      • CABA, 아르헨티나, C1199ABB
        • Hospital Italiano de Buenos Aires
      • CABA, 아르헨티나, C1055AAO
        • Buenos Aires Skin
      • CABA, 아르헨티나, C1056ABH
        • Investigaciones Medicas IMOBA SRL
      • CABA, 아르헨티나, C1128
        • Mautalen Salud e Investigacion
      • Caba, 아르헨티나, C1122AAF
        • Halitus Instituto Medico S.A. - Dermatologia y Estetica
      • Rosario, 아르헨티나, S2000DBS
        • Instituto De Especialidades De La Salud SRL
      • San Fernando, 아르헨티나, B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán, 아르헨티나, T4000
        • Instituto de Investigaciones Medicas Tucuman
      • Dudley, 영국, DY1 2HQ
        • Dudley Group NHS Foundation Trust
      • Harrow, 영국, HA1 3UJ
        • London North West University Healthcare NHS Trust
      • Kings Lynn, 영국, PE30 4ET
        • The Queen Elizabeth Hospital NHS Foundation Trust
      • London, 영국, SE1 9RT
        • Guys and St Thomas NHS Foundation Trust
      • Reading, 영국, RG1 5AN
        • Royal Berkshire Hospital
      • Salford, 영국, M6 8HD
        • Salford Royal Hospital
      • Southampton, 영국, So166yd
        • University Hospital Southampton
      • Wakefield, 영국, WF1 4DG
        • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
      • Feldkirch, 오스트리아, 6800
        • LKH Feldkirch
      • Linz, 오스트리아, 4020
        • Kepler Universitatsklinikum GmbH
      • Sankt Pölten, 오스트리아, 3100
        • Universtitatsklinikum St Poelten
      • Vienna, 오스트리아, 1090
        • Allgemeines Krankenhaus der Stadt Wien
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, 캐나다, A1E 1V4
        • Skincare Studio Inc Dermatology Clinical Trials
    • Ontario
      • Ajax, Ontario, 캐나다, L1S7K8
        • CCA Medical Research Corporation
      • Barrie, Ontario, 캐나다, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton, Ontario, 캐나다, L8N 1Y2
        • Dermatrials Research
      • London, Ontario, 캐나다, N6A 5R9
        • Lovegrove Dermatology
      • Markham, Ontario, 캐나다, L3P 1X3
        • Lynderm Research Inc.
      • Waterloo, Ontario, 캐나다, N2J 1C4
        • Alliance Clinical Trials
    • Quebec
      • Montreal, Quebec, 캐나다, H2X 2V1
        • Innovaderm Research Inc.
      • Québec, Quebec, 캐나다, G1W 4R4
        • The Centre de recherche Saint-Louis
      • Guimarães, 포르투갈, 4835 044
        • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
      • Leiria, 포르투갈, 2410 197
        • Unidade Local De Saude Da Regiao De Leiria Epe
      • Lisbon, 포르투갈, 1169 050
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon, 포르투갈, 1998 018
        • Hosp. Cuf Descobertas
      • Porto, 포르투갈, 4099 001
        • Ulssa Hosp. Santo Antonio
      • Bialystok, 폴란드, 15 375
        • Specderm Poznanska sp j
      • Bialystok, 폴란드, 15-351
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Elblag, 폴란드, 82 300
        • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
      • Katowice, 폴란드, 40 568
        • Care Clinic Sp z o o
      • Krakow, 폴란드, 30 002
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Lodz, 폴란드, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Olsztyn, 폴란드, 10-117
        • Etyka Osrodek Badan Klinicznych
      • Poznan, 폴란드, 60 529
        • SOLUMED Centrum Medyczne
      • Skierniewice, 폴란드, 96 100
        • Velocity Nova Sp z o o
      • Warsaw, 폴란드, 02 661
        • Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
      • Warsaw, 폴란드, 02 953
        • Klinika Ambroziak Dermatologia
      • Wroclaw, 폴란드, 52 416
        • Centrum Medyczne Oporow
      • Wroclaw, 폴란드, 51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Budapest, 헝가리, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest, 헝가리, 1152
        • Uno Medical Trials Ltd.
      • Debrecen, 헝가리, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen, 헝가리, 4031
        • Derma-B Kft
      • Gyula, 헝가리, 5700
        • Synexus Magyarorszag Kft
      • Gyöngyös, 헝가리, 3200
        • Gyongyosi Bugat Pal Korhaz
      • Hódmezővásárhely, 헝가리, 6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kaposvár, 헝가리, 7400
        • Somogy Varmegyei Kaposi Mor Oktato Korhaz
      • Kecskemét, 헝가리, 6000
        • Bacs-kiskun Megyei Korhaz
      • Szolnok, 헝가리, 5000
        • Allergo-Derm Bakos Kft.
      • Veszprém, 헝가리, 8200
        • Medmare Egeszsegugyi Es Szolgaltato Bt.
      • Clayton, 호주, 3168
        • Monash Medical Centre
      • Coorparoo, 호주, 4151
        • Cornerstone Dermatology
      • Greenslopes, 호주, 4120
        • Veracity Clinical Research
      • Kogarah, 호주, 2217
        • Premier Specialists
      • Melbourne, 호주, 3004
        • The Alfred Hospital
      • Melbourne, 호주, 3050
        • Royal Melbourne Hospital
      • Mitcham, 호주, 3132
        • ISHI dermatology
      • Westmead, 호주, 2145
        • Westmead Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

12년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

  • Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
  • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm 1: JNJ 77242113

Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

위약 비교기: Arm 2: Placebo

Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Matching placebo will be administered orally.

활성 비교기: Arm 3: Ustekinumab

Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.

JNJ-77242113 will be administered orally.

Matching placebo will be administered orally.

Ustekinumab will be administered subcutaneously.

다른 이름들:
  • 스텔라라
  • CNTO 1275

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
기간: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
기간: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16

2차 결과 측정

결과 측정
측정값 설명
기간
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
기간: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
기간: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
기간: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
기간: Week 28

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
기간: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
기간: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
기간: Week 16

PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
기간: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Up to Week 108

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important.

Up to Week 108
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
기간: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
기간: Baseline up to Week 16

DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
기간: Week 16

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
기간: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
기간: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
기간: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
기간: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
기간: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
기간: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
기간: Baseline up to Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
기간: Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
기간: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
기간: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
기간: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
기간: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 15일

기본 완료 (실제)

2025년 11월 17일

연구 완료 (추정된)

2027년 8월 20일

연구 등록 날짜

최초 제출

2025년 4월 11일

QC 기준을 충족하는 최초 제출

2025년 4월 11일

처음 게시됨 (실제)

2025년 4월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 77242113PSO3006
  • 77242113PSO3006 (기타 식별자: Janssen Research & Development, LLC)
  • 2024-515706-77-00 (레지스트리 식별자: EUCT number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다